{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:33:11Z","timestamp":1791516791341,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s12325-013-0009-4","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T14:01:18Z","timestamp":1361282478000},"page":"81-101","source":"Crossref","is-referenced-by-count":50,"title":["Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes"],"prefix":"10.1007","volume":"30","author":[{"given":"Michael","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,13]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364\u20131379.","journal-title":"Diabetes Care."},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2165\/00002018-200730120-00005","volume":"30","author":"K Hermansen","year":"2007","unstructured":"Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30:1127\u20131142.","journal-title":"Drug Saf."},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","volume":"2","author":"N McIntyre","year":"1964","unstructured":"McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet. 1964;2:20\u201321.","journal-title":"Lancet."},{"key":"9_CR4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","volume":"24","author":"H Elrick","year":"1964","unstructured":"Elrick H, Stimmler L, Hlad CJ, Jr., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076\u20131082.","journal-title":"J Clin Endocrinol Metab."},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","volume":"46","author":"MJ Perley","year":"1967","unstructured":"Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954\u20131962.","journal-title":"J Clin Invest."},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","volume":"37","author":"J Dupre","year":"1973","unstructured":"Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826\u2013828.","journal-title":"J Clin Endocrinol Metab."},{"key":"9_CR7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF00291980","volume":"28","author":"WE Schmidt","year":"1985","unstructured":"Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985;28:704\u2013707.","journal-title":"Diabetologia."},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.85.10.3575","volume":"85","author":"CF Deacon","year":"2000","unstructured":"Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85:3575\u20133581.","journal-title":"J Clin Endocrinol Metab."},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/en.140.11.5356","volume":"140","author":"L Hansen","year":"1999","unstructured":"Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7\u201336)amide is transformed to glucagon-like peptide-1-(9\u201336) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356\u20135363.","journal-title":"Endocrinology."},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46\u201352.","journal-title":"Diabetologia."},{"key":"9_CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","volume":"52","author":"PV Hojberg","year":"2009","unstructured":"Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199\u2013207.","journal-title":"Diabetologia."},{"key":"9_CR12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u20132157.","journal-title":"Gastroenterology."},{"key":"9_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3810\/pgm.2009.05.1997","volume":"121","author":"M Nauck","year":"2009","unstructured":"Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med. 2009;121:5\u201315.","journal-title":"Postgrad Med."},{"key":"9_CR14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728\u2013742.","journal-title":"Nat Rev Endocrinol."},{"key":"9_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1463-1326.2012.01628.x","volume":"15","author":"JJ Holst","year":"2013","unstructured":"Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab. 2013;15:3\u201314.","journal-title":"Diabetes Obes Metab."},{"key":"9_CR16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","volume":"52","author":"LL Kjems","year":"2003","unstructured":"Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380\u2013386.","journal-title":"Diabetes."},{"key":"9_CR17","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.2337\/diacare.26.10.2860","volume":"26","author":"B Ahren","year":"2003","unstructured":"Ahren B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care. 2003;26:2860\u20132864.","journal-title":"Diabetes Care."},{"key":"9_CR18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/CS20090464","volume":"122","author":"L Wu","year":"2012","unstructured":"Wu L, Olverling A, Huang Z, et al. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats. Clin Sci (Lond). 2012;122:375\u2013384.","journal-title":"Clin Sci (Lond)."},{"key":"9_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1677\/jme.0.0190241","volume":"19","author":"Y Wang","year":"1997","unstructured":"Wang Y, Kole HK, Montrose-Rafizadeh C, Perfetti R, Bernier M, Egan JM. Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J Mol Endocrinol. 1997;19:241\u2013248.","journal-title":"J Mol Endocrinol."},{"key":"9_CR20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0016-5085(85)90650-X","volume":"89","author":"JN Hunt","year":"1985","unstructured":"Hunt JN, Smith JL, Jiang CL. Effect of meal volume and energy density on the gastric emptying of carbohydrates. Gastroenterology. 1985;89:1326\u20131330.","journal-title":"Gastroenterology."},{"key":"9_CR21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0016-5085(83)80232-7","volume":"85","author":"W Brener","year":"1983","unstructured":"Brener W, Hendrix TR, McHugh PR. Regulation of the gastric emptying of glucose. Gastroenterology. 1983;85:76\u201382.","journal-title":"Gastroenterology."},{"key":"9_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00265086","volume":"32","author":"M Horowitz","year":"1989","unstructured":"Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:151\u2013159.","journal-title":"Diabetologia."},{"key":"9_CR23","first-page":"1643","volume":"37","author":"KL Jones","year":"1996","unstructured":"Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med. 1996;37:1643\u20131648.","journal-title":"J Nucl Med."},{"key":"9_CR24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1023\/A:1022528414264","volume":"48","author":"S Gonlachanvit","year":"2003","unstructured":"Gonlachanvit S, Hsu CW, Boden GH, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci. 2003;48:488\u2013497.","journal-title":"Dig Dis Sci."},{"key":"9_CR25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1464-5491.2011.03496.x","volume":"29","author":"J Ma","year":"2012","unstructured":"Ma J, Pilichiewicz AN, Feinle-Bisset C, et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med. 2012;29:604\u2013608.","journal-title":"Diabet Med."},{"key":"9_CR26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1210\/jc.2009-1503","volume":"95","author":"AM Deane","year":"2010","unstructured":"Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215\u2013221.","journal-title":"J Clin Endocrinol Metab."},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ajcn\/68.3.525","volume":"68","author":"E Naslund","year":"1998","unstructured":"Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998;68:525\u2013530.","journal-title":"Am J Clin Nutr."},{"key":"9_CR28","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2005-2220","volume":"91","author":"TJ Little","year":"2006","unstructured":"Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91:1916\u20131923.","journal-title":"J Clin Endocrinol Metab."},{"key":"9_CR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1210\/jc.81.1.327","volume":"81","author":"B Willms","year":"1996","unstructured":"Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81:327\u2013332.","journal-title":"J Clin Endocrinol Metab."},{"key":"9_CR30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/CCM.0b013e3181d9d87a","volume":"38","author":"AM Deane","year":"2010","unstructured":"Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010;38:1261\u20131269.","journal-title":"Crit Care Med."},{"key":"9_CR31","first-page":"E981","volume":"273","author":"MA Nauck","year":"1997","unstructured":"Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981\u2013E988.","journal-title":"Am J Physiol."},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.2337\/diabetes.54.7.2212","volume":"54","author":"JJ Meier","year":"2005","unstructured":"Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005;54:2212\u20132218.","journal-title":"Diabetes."},{"key":"9_CR33","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","volume":"60","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561\u20131565.","journal-title":"Diabetes."},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.ijo.0801627","volume":"25","author":"A Flint","year":"2001","unstructured":"Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001;25:781\u2013792.","journal-title":"Int J Obes Relat Metab Disord."},{"key":"9_CR35","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824\u2013830.","journal-title":"Lancet."},{"key":"9_CR36","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.2337\/db09-1886","volume":"59","author":"DF Gaddy","year":"2010","unstructured":"Gaddy DF, Riedel MJ, Pejawar-Gaddy S, Kieffer TJ, Robbins PD. In vivo expression of HGF\/NK1 and GLP-1 from dsAAV vectors enhances pancreatic ss-cell proliferation and improves pathology in the db\/db mouse model of diabetes. Diabetes. 2010;59:3108\u20133116.","journal-title":"Diabetes."},{"key":"9_CR37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/db09-0063","volume":"58","author":"M Cornu","year":"2009","unstructured":"Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, Thorens B. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2\/IGF-1 receptor autocrine loop. Diabetes. 2009;58:1816\u20131825.","journal-title":"Diabetes."},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153\u2013165.","journal-title":"Cell Metab."},{"key":"9_CR39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2146\/ajhp050459","volume":"63","author":"GM Bray","year":"2006","unstructured":"Bray GM. Exenatide. Am J Health Syst Pharm. 2006;63:411\u2013418.","journal-title":"Am J Health Syst Pharm."},{"key":"9_CR40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1517\/13543780902766802","volume":"18","author":"J Malone","year":"2009","unstructured":"Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18:359\u2013367.","journal-title":"Expert Opin Investig Drugs."},{"key":"9_CR41","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2337\/diacare.25.8.1398","volume":"25","author":"B Elbrond","year":"2002","unstructured":"Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398\u20131404.","journal-title":"Diabetes Care."},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12325-010-0110-x","volume":"28","author":"A Flint","year":"2011","unstructured":"Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28:213\u2013226.","journal-title":"Adv Ther."},{"key":"9_CR43","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","volume":"53","author":"KB Degn","year":"2004","unstructured":"Degn KB, Juhl CB, Sturis J, et al. One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187\u20131194.","journal-title":"Diabetes."},{"key":"9_CR44","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240\u20131250.","journal-title":"Lancet."},{"key":"9_CR45","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","volume":"13","author":"MB DeYoung","year":"2011","unstructured":"DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13:1145\u20131154.","journal-title":"Diabetes Technol Ther."},{"issue":"Suppl.1","key":"9_CR46","volume":"57","year":"2008","unstructured":"Distiller L, Ruus P. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients. Diabetes Care. 2008;57(Suppl. 1):Abstract A154.","journal-title":"Diabetes Care."},{"key":"9_CR47","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.","journal-title":"BMJ."},{"key":"9_CR48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1530\/EJE-09-0101","volume":"160","author":"M Monami","year":"2009","unstructured":"Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160:909\u2013917.","journal-title":"Eur J Endocrinol."},{"key":"9_CR49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.beem.2009.03.008","volume":"23","author":"S Madsbad","year":"2009","unstructured":"Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) \u2014 preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009;23:463\u2013477.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"9_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1900\/RDS.2009.6.247","volume":"6","author":"B Gallwitz","year":"2009","unstructured":"Gallwitz B. Preclinical and clinical data on extraglycemic effects of GLP-1 receptor agonists. Rev Diabet Stud. 2009;6:247\u2013259.","journal-title":"Rev Diabet Stud."},{"key":"9_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39\u201347.","journal-title":"Lancet."},{"key":"9_CR52","unstructured":"Kapitza C, Coester H-V, Poitiers F, Heumann G, Ruus P, Hincelin-M\u00e9ry A. Pharmacodynamic characteristics of lixisenatide (QD 2) versus liraglutide QD in patients with T2DM inadequately controlled with metformin. Poster presented at: 21st World Diabetes Congress, Dubai, UAE, December 8 2011. Abstract D-0740."},{"key":"9_CR53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","volume":"154","author":"JB Buse","year":"2011","unstructured":"Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103\u2013112.","journal-title":"Ann Intern Med."},{"key":"9_CR54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2012.01560.x","volume":"14","author":"MS Fineman","year":"2012","unstructured":"Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14:675\u2013688.","journal-title":"Diabetes Obes Metab."},{"key":"9_CR55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","volume":"151","author":"H Linnebjerg","year":"2008","unstructured":"Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123\u2013129.","journal-title":"Regul Pept."},{"key":"9_CR56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0950-3528(91)90034-X","volume":"5","author":"M Horowitz","year":"1991","unstructured":"Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol. 1991;5:371\u2013407.","journal-title":"Baillieres Clin Gastroenterol."},{"key":"9_CR57","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2004.09.055","volume":"127","author":"HP Parkman","year":"2004","unstructured":"Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592\u20131622.","journal-title":"Gastroenterology."},{"key":"9_CR58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cgh.2008.01.009","volume":"6","author":"LA Szarka","year":"2008","unstructured":"Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol. 2008;6:635\u2013643, e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9_CR59","first-page":"3","volume":"9","author":"F Perri","year":"2005","unstructured":"Perri F, Pastore MR, Annese V. 13C-octanoic acid breath test for measuring gastric emptying of solids. Eur Rev Med Pharmacol Sci. 2005;9:3\u20138.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"9_CR60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","volume":"14","author":"J Jelsing","year":"2012","unstructured":"Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying \u2014 long lasting effects on body weight. Diabetes Obes Metab. 2012;14:531\u2013538.","journal-title":"Diabetes Obes Metab."},{"key":"9_CR61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CE.S15525","volume":"6","author":"A Barnett","year":"2011","unstructured":"Barnett A. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evidence. 2011;6:67\u201379.","journal-title":"Core Evidence."},{"key":"9_CR62","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","volume":"14","author":"Y Seino","year":"2012","unstructured":"Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14:910\u2013917.","journal-title":"Diabetes Obes Metab."},{"key":"9_CR63","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7150\/ijms.4128","volume":"9","author":"F Zhang","year":"2012","unstructured":"Zhang F, Tang X, Cao H, et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci. 2012;9:574\u2013581.","journal-title":"Int J Med Sci."},{"key":"9_CR64","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/(SICI)1096-9136(199610)13:10<902::AID-DIA242>3.0.CO;2-O","volume":"13","author":"T Yagi","year":"1996","unstructured":"Yagi T, Nishi S, Hinata S, Murakami M, Yoshimi T. A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects. Diabet Med. 1996;13:902\u2013907.","journal-title":"Diabet Med."},{"key":"9_CR65","first-page":"1024","volume":"27","author":"RE Ratner","year":"2010","unstructured":"Ratner RE, Rosenstock J, Boka G, Investigators DRIS. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27:1024\u20131032.","journal-title":"Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med."},{"key":"9_CR66","doi-asserted-by":"crossref","first-page":"A212","DOI":"10.2337\/db12-836-1328","volume":"61","author":"R Becker","year":"2012","unstructured":"Becker R, Stechl J, Kapitza C, Msihid J. Augmentation of 1st-phase insulin release with lixisenatide in non-diabetic subjects. Diabetes. 2012;61:A212\u2013A344. Abstract 1149-P.","journal-title":"Diabetes."},{"key":"9_CR67","doi-asserted-by":"crossref","first-page":"A212","DOI":"10.2337\/db12-836-1328","volume":"61","author":"RH Becker","year":"2012","unstructured":"Becker RH, Kapitza C, Stechl J, Ruus P, Msihid J. Restitution of glucose disposition with lixisenatide in T2DM subjects. Diabetes. 2012;61:A212\u2013A344. Abstract 1081-P.","journal-title":"Diabetes."},{"key":"9_CR68","doi-asserted-by":"crossref","first-page":"A212","DOI":"10.2337\/db12-836-1328","volume":"61","author":"M Lorenz","year":"2012","unstructured":"Lorenz M, Pfeiffer C, Steinstr\u00e4\u00dfer A, Ruus P. Effects of lixisenatide once daily on gastric emptying and relationship to postprandial glycemia in type 2 diabetes mellitus. Diabetes. 2012;61:A212\u2013A344. Abstract 1085-P.","journal-title":"Diabetes."},{"key":"9_CR69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0016-5085(97)70080-5","volume":"113","author":"E Schvarcz","year":"1997","unstructured":"Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113:60\u201366.","journal-title":"Gastroenterology."},{"issue":"Suppl.1","key":"9_CR70","first-page":"A212","volume":"61","author":"M Riddle","year":"2012","unstructured":"Riddle M, Home P, Marre M, Niemoeller E, Ping L, Rosenstock J. Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin \u00b1 metformin: GetGoal-L Study. Diabetes. 2012;61(Suppl. 1): A212\u2013A344. Abstract 983-P.","journal-title":"Diabetes."},{"key":"9_CR71","unstructured":"Rosenstock J, Forst T, Aronson R, et al. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes: GetGoal-Duo 1 Study. Presented at: 72nd Scientific Sessions of the American Diabetes Association, Philadelphia PA, 8\u201312 June 2012. Abstract 62-OR."},{"key":"9_CR72","unstructured":"Ahr\u00e9n B, Dimas L, Miossec P, Saubado S, Aronson R. Efficacy and safety of lixisenatide QD morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M). Oral presentation at the 21st World Diabetes Congress, Dubai, UAE, December 8 2011. Abstract 0-0591."},{"key":"9_CR73","first-page":"1","volume":"54Suppl.1","author":"R Ratner","year":"2011","unstructured":"Ratner R, Hanefield M, Shamanna P, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea + metformin (GetGoal-S). Poster presented at: 47th Annual Meeting of the European Association for the Study of Diabetes, September 12\u201316 2011, Lisbon, Portugal. Diabetologia. 2011;54(Suppl. 1):1\u2013542. Abstract 785.","journal-title":"Poster presented at: 47th Annual Meeting of the European Association for the Study of Diabetes, September 12\u201316 2011, Lisbon, Portugal. Diabetologia"},{"issue":"Suppl.1","key":"9_CR74","first-page":"A212","volume":"61","author":"M Pinget","year":"2012","unstructured":"Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes. 2012;61(Suppl. 1):A212\u2013A344. Abstract 1010-P.","journal-title":"Diabetes."},{"issue":"Suppl.1","key":"9_CR75","first-page":"1","volume":"54","author":"J Rosenstock","year":"2011","unstructured":"Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in patients with T2DM insufficiently controlled on metformin (GetGoal-X). Poster presented at: 47th Annual Meeting of the European Association for the Study of Diabetes, September 12\u201316 2011, Lisbon, Portugal. Diabetologia. 2011;54(Suppl. 1):1\u2013542. Abstract 786.","journal-title":"Poster presented at: 47th Annual Meeting of the European Association for the Study of Diabetes, September 12\u201316 2011, Lisbon, Portugal. Diabetologia"},{"issue":"Suppl.1","key":"9_CR76","first-page":"1","volume":"54","author":"G Bolli","year":"2011","unstructured":"Bolli G, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Hanefield M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1). Poster presented at: 47th Annual Meeting of the European Association for the Study of Diabetes, September 12\u201316 2011, Lisbon, Portugal. Diabetologia. 2011;54(Suppl. 1):1\u2013542. Abstract 784.","journal-title":"Poster presented at: 47th Annual Meeting of the European Association for the Study of Diabetes, September 12\u201316 2011, Lisbon, Portugal. Diabetologia"},{"key":"9_CR77","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","volume":"35","author":"VA Fonseca","year":"2012","unstructured":"Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35:1225\u20131231.","journal-title":"Diabetes Care."},{"key":"9_CR78","doi-asserted-by":"crossref","first-page":"A212","DOI":"10.2337\/db12-836-1328","volume":"61","author":"D Raccah","year":"2012","unstructured":"Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich JE. Efficacy and safety of lixisenatide in elderly (\u226565 yr) and very elderly (\u226575 yr) patients with type 2 diabetes: an analysis from the GetGoal phase 3 program. Diabetes. 2012;61:A212\u2013A344. Abstract 972-P.","journal-title":"Diabetes."},{"issue":"Suppl.1","key":"9_CR79","volume":"58","year":"2009","unstructured":"Liu YH, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment. Diabetes. 2009;58(Suppl. 1):Abstract 557-P.","journal-title":"Diabetes."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0009-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T13:47:56Z","timestamp":1595425676000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0009-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0009-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}